LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy
AstraZeneca and Merck’s LYNPARZA Increased the Median Time Without Disease Progression or Death by 4.2 Months Versus Physician’s Choice of Chemotherapy Following Two or More Prior Lines of Chemotherapy
AstraZeneca and Merck’s LYNPARZA is the First and Only PARP Inhibitor to Demonstrate Efficacy Versus Chemotherapy in This Setting
KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States
and Canada), today presented full results from the Phase 3 SOLO3 trial
which evaluated LYNPARZA, compared to chemotherapy, for the treatment of
platinum-sensitive relapsed patients with germline BRCA1/2-mutated
(gBRCAm) advanced ovarian cancer, who have received two more
prior lines of chemotherapy. The results were presented at the 55th
Annual Meeting of the American Society of Clinical Oncology (ASCO) in
Chicago.
Media:
Pamela Eisele
(267) 305-3558
Michael Close
(267) 305-1211
Investors:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
